CVMP: Zenrelia signal management and MI-VeDDRA consultation
A Zenrelia variation adds aggression as a very rare adverse event; separately, the revised MI-VeDDRA terms list was released for consultation.
Zenrelia: signal management outcome
The CVMP adopted a positive opinion on a variation for Zenrelia (ilunocitinib). Following the marketing authorisation holder’s signal management process, “aggression” is to be included in the product information as a very rare adverse event.
MI-VeDDRA: revised list for consultation
The CVMP agreed to release the revised VGVP Module: Medically Important (MI) VeDDRA terms list for a two-month public consultation. The exact submission deadline has not been independently verified here.
Two distinct regulatory procedures
The Zenrelia item concerns a product-specific variation. The MI-VeDDRA list is a draft released for public consultation; its release does not establish a final, generally applicable new GVP requirement.
Practical implications
For Zenrelia, monitor the final approved product information. Pharmacovigilance teams should compare the draft MI-VeDDRA list with the previous version, document relevant terminology changes and prepare comments based on the official consultation document.
Official primary source
EMA: CVMP Meeting Highlights, 3–5 November 2026 (published 6 November 2026)
As of 13 November 2026. Scientific interpretation; official source documents take precedence.
